In a human clinical study conducted by SIBR Research Inc. it was demonstrated that the use of Diabetinol over a three-month period, was safe and effective in significantly reducing glucose intolerance in subjects with impaired fasting glucose (IFG), who were also taking oral medication. Diabetinol significantly reduced total cholesterol and LDL cholesterol. Decreasing trends in HbA1c were also observed. The data suggest that Diabetinol as a natural food product may have protective effects in individuals with a combined IFG and hyperlipidemia. For further information: www.kgksynergize.com
Diabetinol Impacts Glycemic Control
Published June 8, 2010
Two studies recently published by the Journal of Functional Foods, sponsored by KGK Synergize Inc., evaluated the safety and efficacy of Diabetinol, a proprietary ingredient, in both an in vivo and a human clinical study. The results of the in vivo study demonstrated that Diabetinol did not produce any adverse effects in a fructose-induced hamster model and showed improvement in blood glucose, insulin, cholesterol and triglycerides.
